Indian Covid variant detected in Greece

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. ATHENS: Greece has become the latest European nation to detect a case of the Covid-19 variant that has helped drive an explosion in infections in India, authorities said Sunday. The country's public health agency said in a statement that the virus strain was detected in a foreign woman aged 33 who lives in the Athens area and had travelled to Dubai on April 4. The woman had a negative PCR virus test result when she left Dubai, the agency said, adding that the variant was detected during a large collection of samples by health services. "It is the first case of the Indian variant in Greece," a source in the Greek health ministry told AFP on condition of anonymity. The woman had symptoms but was not hospitalised, the agency statement said. Her symptoms have since subsided and her period of quarantine is over. "The B.1.617.1 strain was isolated and originates from Maharashtra in India, the region where this variant was first known by this name," it said. Switzerland on Saturday reported having detected its first case of the Indian variant. Belgian authorities on Thursday said a group of 20 Indian nursing students who arrived from Paris had tested positive for the variant in the country. India's capital New Delhi on Sunday extended its lockdown as the country's Covid-19 crisis grew with infections and deaths hitting record highs. A number of countries have suspended flights from India. To keep reading about Indian Covid variant detected in Greece, Click on the link. Seoul, Korea
http://dlvr.it/RyPr0Q

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint